PhaseBio Pharmaceuticals Inc

PhaseBio Pharmaceuticals — Technical Presentation (November 2021)

43 slides from PhaseBio Pharmaceuticals's technical presentation, Nov 15, 2021

  1. Slide 1: REVERSE-IT Phase 3 Trial: Interim Results Presentation and Roundtable Discussion

    REVERSE-IT Phase 3 Trial: Interim Results Presentation and Roundtable Discussion November 15, 2021

  2. Slide 2: Introduction and Corporate Update

    Introduction and Corporate Update Jonathan Mow Chief Executive Officer, PhaseBio

  3. Slide 3: Forward-looking statements

    This presentation includes forward-looking statements. All statements contained in this presentation other than statements of historical facts, including statements regarding future results of operations and financial position of PhaseBio Pharmaceuticals, Inc. (“we,” “us” or “our”), our business str

  4. Slide 4: Pipeline: A Clinical Stage, Cardiopulmonary Focused Biopharmaceutical Company

    Program Pre-Clinical Phase 1 Phase 2 Phase 3 Commercial Rights Upcoming Milestone Target2 Bentracimab Reversal of Ticagrelor Antiplatelet Activity November 15, 2021 Topline results from Interim Analysis of REVERSE-IT Pemziviptadil Pulmonary Arterial Hypertension (PAH) Mid 2022 Report Phase 2B data P

  5. Slide 5: Why We Are Here Today

    Why We Are Here Today 5 Bentracimab Clinical Overview • Discuss P2Y12 inhibitor class, bentracimab and unmet need • Review published bentracimab Phase 1 trial results • Preview unpublished data from Phase 2A trial REVERSE-IT Phase 3 Interim Results • Describe trial overview and goals • Review clinic

  6. Slide 6: Ideal ticagrelor reversal agent criteria

    • At the outset of the bentracimab clinical development program, PhaseBio set out criteria for what an ideal ticagrelor reversal agent would look like ⎯ Because it was a theoretical exercise, the bar was set high • Specifically, we aspired to develop a product that was: 1. Safe: patients requiring r

  7. Slide 7: Bentracimab key takeaways

    • Bentracimab delivers immediate and sustained restoration of platelet function in both healthy subjects and in patients requiring urgent surgery or invasive procedure, or experiencing uncontrolled major or life- threatening bleeding events • Results from the interim analysis of the Phase 3 REVERSE-

  8. Slide 8: Discussion Panel Participants

    Discussion Panel Participants 8 Deepak L. Bhatt, MD, MPH Executive Director of Interventional Cardiovascular Programs, Brigham and Women's Hospital and Professor of Medicine at Harvard Medical School Charles Pollack, MD, MA, FACEP Clinician-Scientist, Department of Emergency Medicine, University of

  9. Slide 9: AHA Analyst Call Agenda

    Agenda 9 AHA Analyst Call Agenda: November 15th, 12:30pm ET Presenter Time Introductory Remarks Jonathan Mow, PhaseBio Chief Executive Officer 12:30-12:35 Bentracimab Pivotal Program Overview Dr. John Lee, PhaseBio Chief Medical Officer 12:35-12:40 REVERSE-IT AHA Slide Presentation Dr. Bhatt 12:40-1

  10. Slide 10: Bentracimab Pivotal Program Overview

    Bentracimab Pivotal Program Overview John Lee, MD, PhD Chief Medical Officer, PhaseBio

  11. Slide 11: Timelines of Bentracimab Program

    bentracimab Timelines of Bentracimab Program 11 2019 2020 2021 2022 2023 Phase 2B: 50-80 year old volunteersPhase 2APhase 1 NEJM FDA Breakthrough Therapy FDA EOP1 EMA PRIME Designation N=200, 150 randomized to receive bentracimab N=150, major bleeding + urgent surgery patients Final N=200 Post -appr

  12. Slide 12: Phase 2B: Reversal of Ticagrelor and Safety

    Phase 2B: Reversal of Ticagrelor and Safety Bentracimab achieved primary endpoint of ticagrelor reversal measured by VerifyNow P2Y12 assay • Statistically significant reduction in % inhibition of PRU within 4 hours • Extent of reversal similar to results observed in Phase 1 and 2A studies Safety pro

  13. Slide 13: REVERSE-IT Phase 3 Trial: Results from Prespecified Interim Analysis

    REVERSE-IT Phase 3 Trial: Results from Prespecified Interim Analysis Deepak L. Bhatt, MD, MPH Executive Director of Interventional Cardiovascular Programs, Brigham and Women's Hospital and Professor of Medicine at Harvard Medical School

  14. Slide 14: REVERSE-IT: Effect of Bentracimab on Platelet Inhibition and Hemostasis

    REVERSE-IT: Effect of Bentracimab on Platelet Inhibition and Hemostasis in Patients on Ticagrelor with Major Bleeding or Requiring Urgent Procedures Deepak L. Bhatt, MD, MPH, Charles V. Pollack, Jr., MD, C. David Mazer, MD, Dominick J. Angiolillo, MD, PhD, Ph. Gabriel Steg, MD, Stefan K. James, MD,

  15. Slide 15: Disclosures

    Disclosures Dr. Deepak L. Bhatt discloses the following relationships - Advisory Board: Boehringer Ingelheim, Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, Janssen, Level Ex, Medscape Cardiology, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Regado Bioscien

  16. Slide 16: Ticagrelor: Substantial Data, with Broad Label

    Ticagrelor: Substantial Data, with Broad Label • Ticagrelor is an oral P2Y12 inhibitor that is effective (and FDA- approved) in patients with acute coronary syndromes, prior myocardial infarction, high-risk coronary artery disease, transient ischemic attack, and stroke, based on PLATO,1,2 PEGASUS,3,

  17. Slide 17: Ticagrelor: Reversible Mechanism of Action

    Ticagrelor: Reversible Mechanism of Action Bhatt DL. Nature Reviews Cardiology. 2009;6:737-38.

  18. Slide 18: Bentracimab: An Intravenous Monoclonal Antibody

    Bentracimab: An Intravenous Monoclonal Antibody The P2Y12 receptor is activated by adenosine diphosphate (ADP) (A). On platelets, ticagrelor reversibly binds to the P2Y12 receptor. This induces a conformational change which prevents ADP from signaling through to the P2Y12 receptor, inhibiting platel

  19. Slide 19: Immediate Onset and Sustained Duration of Ticagrelor Reversal

    Immediate Onset and Sustained Duration of Ticagrelor Reversal Using Bentracimab (formerly PB2452) P values by timepoint for each cohort Cohort 5min 0.25h 0.5h 1h 2h 3h 6h 8h 10h 12h 16h 20h 7 0.040 0.040 0.131 0.037 0.040 0.019 0.019 0.019 0.152 0.019 0.019 0.224 8 0.019 0.019 0.019 0.019 0.019 0.01

  20. Slide 20: Bentracimab Phase 2A Data

    Bentracimab Phase 2A Data Adverse Events PBO (N=6) Bentracimab (N=17) Any AE – no. 13 20 Subjects with AE – no. (%) 5 (83%) 10 (59%) Dry mouth 1 0 Infrequent bowel movements 1 0 Nausea 1 1 Feeling hot (r) 0 2 Infusion site bruising 1 0 Infusion site erythema 1 0 Infusion site extravasation 0 1 Vesse

  21. Slide 21: REVERSE-IT: Enrollment and Study Design

    REVERSE-IT: Enrollment and Study Flowchart REVERSE-IT Study Design Multicenter, open-label, prospective single-arm study of reversal of the antiplatelet effects of ticagrelor with bentracimab in at least 200 patients who present with uncontrolled major or life-threatening bleeding or who require urg

  22. Slide 22: REVERSE-IT: Endpoints

    REVERSE-IT: Endpoints Primary Reversal Endpoint The minimum % inhibition of PRU within 4 hours of bentracimab initiation as assessed by the Verify Now™ PRUTest™ platelet function assay Primary Hemostasis Endpoint (Will be Centrally Adjudicated) Achievement of effective hemostasis within 24 hours aft

  23. Slide 23: REVERSE-IT Study Committees

    REVERSE-IT Study Committees Steering Committee Deepak L. Bhatt MD, MPH (Chair), Dominick J. Angiolillo, MD, PhD, Stefan K. James, MD, PhD, Charles V. Pollack, Jr., MA, MD, Ph. Gabriel Steg, MD, Subodh Verma, MD, PhD, Jeffrey I. Weitz, MD Data Safety Monitoring Board W. Frank Peacock, MD, (Chair), De

  24. Slide 24: REVERSE-IT Investigators

    REVERSE-IT Investigators REVERSE-IT Investigators Mentor Ahmeti, MD, Denis Angoulvant, MD, PhD, Craig Brown, MD, Warren Cantor, MD, Michael Charles, MD, Marc Claeys, MD, PhD, Francesco Franchi, MD, Alex Gregory, MD, Zafir Hawa, MD, Michael Heffernan, MD, John Kotter, MD, Gilles Lemesle, MD, PhD, Dav

  25. Slide 25: REVERSE-IT: Enrollment and Study Flowchart

    REVERSE-IT: Enrollment and Study Flowchart

  26. Slide 26: REVERSE-IT: Baseline Characteristics

    REVERSE-IT: Baseline Characteristics

  27. Slide 27: REVERSE-IT: Platelet Function Tests, Percent Inhibition of PRU

    REVERSE-IT: Platelet Function Tests Percent Inhibition of PRU PRU Analysis of Reversal Ticagrelor Reversal with VerifyNow PRU. Ticagrelor reversal is shown as a reduction in % inhibition of PRU or PRI and as an increase in PRU or platelet reactivity index at multiple timepoints post-treatment. Shown

  28. Slide 28: REVERSE-IT: Platelet Function Tests, PRI Analysis

    REVERSE-IT: Platelet Function Tests PRI analysis of ReversalPercent Inhibition of PRI Ticagrelor Reversal with VASP platelet reactivity index (PRI). Comparison of % inhibition of platelet reactivity index pre- treatment and the minimum % inhibition of platelet reactivity index within 4 hours of init

  29. Slide 29: REVERSE-IT: Reversal in Surgical and Bleeding Patients

    REVERSE-IT: Reversal in Surgical and Bleeding Pts PRU analysis in surgical and bleeding patients PRI analysis in surgical and bleeding patients Ticagrelor Reversal in Bleeding and Surgical Patients. Multiple platelet function assays were used to measure extent of ticagrelor reversal in bleeding and

  30. Slide 30: REVERSE-IT: Subgroups Forest Plot for % Inhibition of PRU

    REVERSE-IT: Platelet Function Tests Subgroups Forest Plot for % Inhibition of PRU Prespecified Subgroup Analyses of the Primary Reversal Endpoint. The primary reversal endpoint was the minimum % inhibition of PRU within 4 hours of study drug initiation compared to pre-treatment % inhibition of PRU.

  31. Slide 31: Enrollment of Urgent Surgical and Major Bleeding Patients

    Enrollment of Urgent Surgical and Major Bleeding Patients in REVERSE-IT Enrolled Urgent Surgical and Major Bleeding Patients

  32. Slide 32: REVERSE-IT: Adjudicated Surgical Hemostasis

    REVERSE-IT: Adjudicated Surgical Hemostasis Adjudicated and Investigator-Reported Surgical Outcomes

  33. Slide 33: REVERSE-IT: Adjudicated Bleeding Hemostasis

    REVERSE-IT: Adjudicated Bleeding Hemostasis Adjudicated and Investigator-Reported Bleeding Outcomes

  34. Slide 34: REVERSE-IT: Adjudicated Hemostasis Subgroups

    REVERSE-IT: Adjudicated Hemostasis Subgroups Forest Plot for Effective Hemostasis (Adjudicated) Prespecified Subgroup Analyses of the Primary Hemostasis Endpoint. The primary hemostasis endpoint was the proportion of patients adjudicated to have achieved effective hemostasis compared to 50% expected

  35. Slide 35: REVERSE-IT: No Platelet Rebound Activity

    REVERSE-IT: No Platelet Rebound Activity P-selectin in surgical and bleeding patients Mean platelet volume in surgical and bleeding patients Effect of Bentracimab Treatment on P-Selectin and Mean Platelet Volume (MPV). Soluble P-selectin and MPV were measured pre-dose and at multiple timepoints post

  36. Slide 36: REVERSE-IT: Adjudicated Thrombotic Events

    REVERSE-IT: Adjudicated Thrombotic Events Adjudicated Thrombotic Events Occurring Post-Reversal

  37. Slide 37: Limitations

    Limitations • There was no control arm, as it was felt to be challenging to randomize to a placebo (as with the NOAC reversal trials). • The majority of surgical patients underwent cardiac surgery, though no reason to think the results don’t apply to other surgeries and invasive procedures. • The nu

  38. Slide 38: Conclusion

    Conclusion • Using the VerifyNow and VASP assays in ticagrelor-treated patients undergoing invasive procedures or with major bleeding, bentracimab, a specific reversal agent for ticagrelor, provided immediate and sustained reversal of ticagrelor’s antiplatelet effects. • Rates of effective hemostasi

  39. Slide 39: Bentracimab for Ticagrelor Reversal in Patients Undergoing Urgent Surgery

    Bentracimab for Ticagrelor Reversal in Patients Undergoing Urgent Surgery Deepak L. Bhatt, MD, MPH, Charles V. Pollack, Jr., MD, C. David Mazer, MD, Dominick J. Angiolillo, MD, PhD, Ph. Gabriel Steg, MD, Stefan K. James, MD, PhD, Jeffrey I. Weitz, MD, Rohit Ramnath, PhD, Susan E. Arnold, PhD, Michae

  40. Slide 40: Thank You!

    TICAGRELOR IN STABLE CAD AND T2D TREATED WITH ASA www.brighamandwomens.org/heart Deepak L. Bhatt, MD, MPH Executive Director, Interventional Cardiovascular Programs, BWH Heart & Vascular Center; Professor of Medicine, Harvard Medical School Email: DLBhattMD@post.Harvard.edu Twitter: @DLBhattMD Thank

  41. Slide 41: REVERSE-IT Prespecified Interim Results Panel Discussion

    REVERSE-IT Phase 3 Trial: Prespecified Interim Results Panel Discussion Deepak L. Bhatt, MD, MPH John Lee, MD, PhD Charles Pollack, MD, MA Ph. Gabriel Steg, MD

  42. Slide 42: Closing Remarks and Q&A

    Closing Remarks and Q&A Jonathan Mow Chief Executive Officer, PhaseBio

  43. Slide 43: PhaseBio Thank you!

    PhaseBio Thank you!

PhaseBio Pharmaceuticals — Technical Presentation (November 2021) on 6ix